Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Weight Management Counseling (WMC)p07 During Primary Care Clerkships: Preceptors Perceived Skills, Attitudes and Frequency of Modeling WMC to Students (P07-001-19).

Ashe K, Clark M, Crawford S, Pbert L, Guck T, Shaw MA, Ockene J.

Curr Dev Nutr. 2019 Jun 13;3(Suppl 1). pii: nzz032.P07-001-19. doi: 10.1093/cdn/nzz032.P07-001-19. eCollection 2019 Jun.

2.

Phosphorylation in two discrete tau domains regulates a stepwise process leading to postsynaptic dysfunction.

Teravskis PJ, Oxnard BR, Miller EC, Kemper L, Ashe KH, Liao D.

J Physiol. 2019 Jun 13. doi: 10.1113/JP277459. [Epub ahead of print]

PMID:
31194886
3.

Factors other than hTau overexpression that contribute to tauopathy-like phenotype in rTg4510 mice.

Gamache J, Benzow K, Forster C, Kemper L, Hlynialuk C, Furrow E, Ashe KH, Koob MD.

Nat Commun. 2019 Jun 6;10(1):2479. doi: 10.1038/s41467-019-10428-1.

4.

A Cautionary Tale: Endogenous Biotinylated Proteins and Exogenously-Introduced Protein A Cause Antibody-Independent Artefacts in Western Blot Studies of Brain-Derived Proteins.

Grant MKO, Shapiro SL, Ashe KH, Liu P, Zahs KR.

Biol Proced Online. 2019 Apr 18;21:6. doi: 10.1186/s12575-019-0095-z. eCollection 2019.

5.

Human cerebrospinal fluid 6E10-immunoreactive protein species contain amyloid precursor protein fragments.

Grant MKO, Handoko M, Rozga M, Brinkmalm G, Portelius E, Blennow K, Ashe KH, Zahs KR, Liu P.

PLoS One. 2019 Feb 28;14(2):e0212815. doi: 10.1371/journal.pone.0212815. eCollection 2019.

6.

Exploiting evolution.

Ashe K.

Nat Chem. 2018 Dec;10(12):1173. doi: 10.1038/s41557-018-0183-8. No abstract available.

PMID:
30464325
7.

Compounding Enclosures: Ensuring Safety During the Preparation of Sterile and Nonsterile Formulations.

Ashe K, Baskett D.

Int J Pharm Compd. 2018 Sep-Oct;22(5):387-398.

PMID:
30384337
8.

Students' Report of Preceptor Weight Management Counseling at Eight U.S. Medical Schools.

Geller AC, Ockene JK, Kulkarni M, Churchill LC, Frisard CF, Okuliar CA, Ashe KM, Crawford SL, Shaw MA, White KM, Pbert LA.

Am J Prev Med. 2018 Nov;55(5):e139-e145. doi: 10.1016/j.amepre.2018.06.014.

PMID:
30342638
9.

Food Insecurity and Obesity: Exploring the Role of Social Support.

Ashe KM, Lapane KL.

J Womens Health (Larchmt). 2018 May;27(5):651-658. doi: 10.1089/jwh.2017.6454. Epub 2017 Nov 28.

PMID:
29182494
10.

Design and rationale of the medical students learning weight management counseling skills (MSWeight) group randomized controlled trial.

Ockene JK, Ashe KM, Hayes RB, Churchill LC, Crawford SL, Geller AC, Jolicoeur D, Olendzki BC, Basco MT, Pendharkar JA, Ferguson KJ, Guck TP, Margo KL, Okuliar CA, Shaw MA, Soleymani T, Stadler DD, Warrier SS, Pbert L.

Contemp Clin Trials. 2018 Jan;64:58-66. doi: 10.1016/j.cct.2017.11.006. Epub 2017 Nov 9.

11.

Quantitative Comparison of Dense-Core Amyloid Plaque Accumulation in Amyloid-β Protein Precursor Transgenic Mice.

Liu P, Reichl JH, Rao ER, McNellis BM, Huang ES, Hemmy LS, Forster CL, Kuskowski MA, Borchelt DR, Vassar R, Ashe KH, Zahs KR.

J Alzheimers Dis. 2017;56(2):743-761. doi: 10.3233/JAD-161027.

12.

Caspase-2 cleavage of tau reversibly impairs memory.

Zhao X, Kotilinek LA, Smith B, Hlynialuk C, Zahs K, Ramsden M, Cleary J, Ashe KH.

Nat Med. 2016 Nov;22(11):1268-1276. doi: 10.1038/nm.4199. Epub 2016 Oct 10.

PMID:
27723722
13.

Morris Water Maze Test: Optimization for Mouse Strain and Testing Environment.

Weitzner DS, Engler-Chiurazzi EB, Kotilinek LA, Ashe KH, Reed MN.

J Vis Exp. 2015 Jun 22;(100):e52706. doi: 10.3791/52706.

14.

Quaternary Structure Defines a Large Class of Amyloid-β Oligomers Neutralized by Sequestration.

Liu P, Reed MN, Kotilinek LA, Grant MK, Forster CL, Qiang W, Shapiro SL, Reichl JH, Chiang AC, Jankowsky JL, Wilmot CM, Cleary JP, Zahs KR, Ashe KH.

Cell Rep. 2015 Jun 23;11(11):1760-71. doi: 10.1016/j.celrep.2015.05.021. Epub 2015 Jun 4.

15.

Characterization of a Novel Mouse Model of Alzheimer's Disease--Amyloid Pathology and Unique β-Amyloid Oligomer Profile.

Liu P, Paulson JB, Forster CL, Shapiro SL, Ashe KH, Zahs KR.

PLoS One. 2015 May 6;10(5):e0126317. doi: 10.1371/journal.pone.0126317. eCollection 2015.

16.

Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease.

Ashe KM, Budman E, Bangari DS, Siegel CS, Nietupski JB, Wang B, Desnick RJ, Scheule RK, Leonard JP, Cheng SH, Marshall J.

Mol Med. 2015 Apr 30;21:389-99. doi: 10.2119/molmed.2015.00088.

17.

More than a FAD: the in vivo effects of disease-linked presenilin-1 mutations.

Zahs KR, Ashe KH.

Neuron. 2015 Mar 4;85(5):893-5. doi: 10.1016/j.neuron.2015.02.021.

18.

α-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease.

Bangari DS, Ashe KM, Desnick RJ, Maloney C, Lydon J, Piepenhagen P, Budman E, Leonard JP, Cheng SH, Marshall J, Thurberg BL.

Am J Pathol. 2015 Mar;185(3):651-65. doi: 10.1016/j.ajpath.2014.11.004. Epub 2014 Dec 29.

PMID:
25553976
19.

Longitudinal testing of hippocampal plasticity reveals the onset and maintenance of endogenous human Aß-induced synaptic dysfunction in individual freely behaving pre-plaque transgenic rats: rapid reversal by anti-Aß agents.

Qi Y, Klyubin I, Harney SC, Hu N, Cullen WK, Grant MK, Steffen J, Wilson EN, Do Carmo S, Remy S, Fuhrmann M, Ashe KH, Cuello AC, Rowan MJ.

Acta Neuropathol Commun. 2014 Dec 24;2:175. doi: 10.1186/s40478-014-0175-x.

20.

Delivery of small molecules for bone regenerative engineering: preclinical studies and potential clinical applications.

Laurencin CT, Ashe KM, Henry N, Kan HM, Lo KW.

Drug Discov Today. 2014 Jun;19(6):794-800. doi: 10.1016/j.drudis.2014.01.012. Epub 2014 Feb 6. Review.

21.

β-Amyloid oligomers in aging and Alzheimer's disease.

Zahs KR, Ashe KH.

Front Aging Neurosci. 2013 Jul 4;5:28. doi: 10.3389/fnagi.2013.00028. eCollection 2013.

22.

Brain amyloid-β oligomers in ageing and Alzheimer's disease.

Lesné SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, Bennett DA, Ashe KH.

Brain. 2013 May;136(Pt 5):1383-98. doi: 10.1093/brain/awt062. Epub 2013 Apr 9.

23.

Correlation of specific amyloid-β oligomers with tau in cerebrospinal fluid from cognitively normal older adults.

Handoko M, Grant M, Kuskowski M, Zahs KR, Wallin A, Blennow K, Ashe KH.

JAMA Neurol. 2013 May;70(5):594-9. doi: 10.1001/jamaneurol.2013.48.

24.

Prions, prionoids and pathogenic proteins in Alzheimer disease.

Ashe KH, Aguzzi A.

Prion. 2013 Jan-Feb;7(1):55-9. doi: 10.4161/pri.23061. Epub 2012 Dec 3. Review.

25.

Merits of combination cortical, subcortical, and cerebellar injections for the treatment of Niemann-Pick disease type A.

Bu J, Ashe KM, Bringas J, Marshall J, Dodge JC, Cabrera-Salazar MA, Forsayeth J, Schuchman EH, Bankiewicz KS, Cheng SH, Shihabuddin LS, Passini MA.

Mol Ther. 2012 Oct;20(10):1893-901. doi: 10.1038/mt.2012.118. Epub 2012 Jul 24.

26.

The role of small molecules in musculoskeletal regeneration.

Lo KW, Ashe KM, Kan HM, Laurencin CT.

Regen Med. 2012 Jul;7(4):535-49. doi: 10.2217/rme.12.33. Review.

27.

Evaluating the feasibility of utilizing the small molecule phenamil as a novel biofactor for bone regenerative engineering.

Lo KW, Ulery BD, Kan HM, Ashe KM, Laurencin CT.

J Tissue Eng Regen Med. 2014 Sep;8(9):728-36. doi: 10.1002/term.1573. Epub 2012 Jul 19.

PMID:
22815259
28.

Genotype-specific differences between mouse CNS stem cell lines expressing frontotemporal dementia mutant or wild type human tau.

Orr ME, Pitstick R, Canine B, Ashe KH, Carlson GA.

PLoS One. 2012;7(6):e39328. doi: 10.1371/journal.pone.0039328. Epub 2012 Jun 18.

29.

Studies of bone morphogenetic protein-based surgical repair.

Lo KW, Ulery BD, Ashe KM, Laurencin CT.

Adv Drug Deliv Rev. 2012 Sep;64(12):1277-91. doi: 10.1016/j.addr.2012.03.014. Epub 2012 Apr 2. Review.

30.

Elevated mercury concentrations in humans of Madre de Dios, Peru.

Ashe K.

PLoS One. 2012;7(3):e33305. doi: 10.1371/journal.pone.0033305. Epub 2012 Mar 16.

31.

Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann-Pick C mice.

Nietupski JB, Pacheco JJ, Chuang WL, Maratea K, Li L, Foley J, Ashe KM, Cooper CG, Aerts JM, Copeland DP, Scheule RK, Cheng SH, Marshall J.

Mol Genet Metab. 2012 Apr;105(4):621-8. doi: 10.1016/j.ymgme.2012.01.020. Epub 2012 Feb 1.

PMID:
22366055
32.

Propagation of tau pathology in a model of early Alzheimer's disease.

de Calignon A, Polydoro M, Suárez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT.

Neuron. 2012 Feb 23;73(4):685-97. doi: 10.1016/j.neuron.2011.11.033. Erratum in: Neuron. 2012 Oct 18;76(2):461.

33.

Neurobiology of disease.

Nelson S, Ashe KH.

Curr Opin Neurobiol. 2011 Dec;21(6):823-6. doi: 10.1016/j.conb.2011.11.001. Epub 2011 Nov 17. No abstract available.

PMID:
22100874
34.

Extended results of the Alzheimer's disease anti-inflammatory prevention trial.

Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, Brandt J, Craft S, Evans DE, Green RC, Ismail MS, Martin BK, Mullan MJ, Sabbagh M, Tariot PN; ADAPT Research Group.

Alzheimers Dement. 2011 Jul;7(4):402-11. doi: 10.1016/j.jalz.2010.12.014.

35.

Grape seed polyphenolic extract specifically decreases aβ*56 in the brains of Tg2576 mice.

Liu P, Kemper LJ, Wang J, Zahs KR, Ashe KH, Pasinetti GM.

J Alzheimers Dis. 2011;26(4):657-66. doi: 10.3233/JAD-2011-110383.

PMID:
21743132
36.

Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease.

Ashe KM, Bangari D, Li L, Cabrera-Salazar MA, Bercury SD, Nietupski JB, Cooper CG, Aerts JM, Lee ER, Copeland DP, Cheng SH, Scheule RK, Marshall J.

PLoS One. 2011;6(6):e21758. doi: 10.1371/journal.pone.0021758. Epub 2011 Jun 29.

37.

Systemic administration of AAV8-α-galactosidase A induces humoral tolerance in nonhuman primates despite low hepatic expression.

Nietupski JB, Hurlbut GD, Ziegler RJ, Chu Q, Hodges BL, Ashe KM, Bree M, Cheng SH, Gregory RJ, Marshall J, Scheule RK.

Mol Ther. 2011 Nov;19(11):1999-2011. doi: 10.1038/mt.2011.119. Epub 2011 Jun 28.

38.

Vesicular monoamine transporter-1 (VMAT-1) mRNA and immunoreactive proteins in mouse brain.

Ashe KM, Chiu WL, Khalifa AM, Nicolas AN, Brown BL, De Martino RR, Alexander CP, Waggener CT, Fischer-Stenger K, Stewart JK.

Neuro Endocrinol Lett. 2011;32(3):253-8.

PMID:
21712771
39.

Rhinovirus contamination of surfaces in homes of adults with natural colds: transfer of virus to fingertips during normal daily activities.

Winther B, McCue K, Ashe K, Rubino J, Hendley JO.

J Med Virol. 2011 May;83(5):906-9. doi: 10.1002/jmv.22027.

PMID:
21412799
40.

The small molecule PKA-specific cyclic AMP analogue as an inducer of osteoblast-like cells differentiation and mineralization.

Lo KW, Kan HM, Ashe KM, Laurencin CT.

J Tissue Eng Regen Med. 2012 Jan;6(1):40-8. doi: 10.1002/term.395. Epub 2011 Feb 10.

41.

Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration.

Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick R, Carlson GA, Lanier LM, Yuan LL, Ashe KH, Liao D.

Neuron. 2010 Dec 22;68(6):1067-81. doi: 10.1016/j.neuron.2010.11.030.

42.

Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.

Marshall J, Ashe KM, Bangari D, McEachern K, Chuang WL, Pacheco J, Copeland DP, Desnick RJ, Shayman JA, Scheule RK, Cheng SH.

PLoS One. 2010 Nov 24;5(11):e15033. doi: 10.1371/journal.pone.0015033.

43.

Activation of cyclic amp/protein kinase: a signaling pathway enhances osteoblast cell adhesion on biomaterials for regenerative engineering.

Lo KW, Ashe KM, Kan HM, Lee DA, Laurencin CT.

J Orthop Res. 2011 Apr;29(4):602-8. doi: 10.1002/jor.21276. Epub 2010 Oct 18.

44.

Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease.

Ashe KM, Taylor KM, Chu Q, Meyers E, Ellis A, Jingozyan V, Klinger K, Finn PF, Cooper CG, Chuang WL, Marshall J, McPherson JM, Mattaliano RJ, Cheng SH, Scheule RK, Moreland RJ.

Mol Genet Metab. 2010 Aug;100(4):309-15. doi: 10.1016/j.ymgme.2010.05.001. Epub 2010 May 5.

PMID:
20554235
45.

Probing the biology of Alzheimer's disease in mice.

Ashe KH, Zahs KR.

Neuron. 2010 Jun 10;66(5):631-45. doi: 10.1016/j.neuron.2010.04.031. Review.

46.

'Too much good news' - are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease?

Zahs KR, Ashe KH.

Trends Neurosci. 2010 Aug;33(8):381-9. doi: 10.1016/j.tins.2010.05.004. Epub 2010 Jun 9. Review.

PMID:
20542579
47.

Effect size of reference memory deficits in the Morris water maze in Tg2576 mice.

Reed MN, Liu P, Kotilinek LA, Ashe KH.

Behav Brain Res. 2010 Sep 1;212(1):115-20. doi: 10.1016/j.bbr.2010.03.037. Epub 2010 Apr 8.

48.

Cognitive effects of cell-derived and synthetically derived Aβ oligomers.

Reed MN, Hofmeister JJ, Jungbauer L, Welzel AT, Yu C, Sherman MA, Lesné S, LaDu MJ, Walsh DM, Ashe KH, Cleary JP.

Neurobiol Aging. 2011 Oct;32(10):1784-94. doi: 10.1016/j.neurobiolaging.2009.11.007. Epub 2010 Jan 19.

49.

Amyloid plaque and neurofibrillary tangle pathology in a regulatable mouse model of Alzheimer's disease.

Paulson JB, Ramsden M, Forster C, Sherman MA, McGowan E, Ashe KH.

Am J Pathol. 2008 Sep;173(3):762-72. doi: 10.2353/ajpath.2008.080175. Epub 2008 Jul 31.

50.

Oligomers of the amyloid-beta protein disrupt working memory: confirmation with two behavioral procedures.

Poling A, Morgan-Paisley K, Panos JJ, Kim EM, O'Hare E, Cleary JP, Lesné S, Ashe KH, Porritt M, Baker LE.

Behav Brain Res. 2008 Nov 21;193(2):230-4. doi: 10.1016/j.bbr.2008.06.001. Epub 2008 Jun 8.

Supplemental Content

Support Center